Male Genitourinary Tumors: Molecular Mechanisms and Potential Therapeutic Targets
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 25 July 2024 | Viewed by 588
Special Issue Editors
Interests: urology; urogenital diseases; surgery
Special Issues, Collections and Topics in MDPI journals
Interests: genitourinary pathology; diagnostic biomarkers; prognostic/predictive biomarkers; digital pathology; emolymphopathology; bladder cancer; prostate cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Genitourinary (GU) tumors are common in men of all ages, with prostate cancer and bladder cancer ranking 1st and 4th among the most prevalent tumors worldwide, respectively. Clinically, GU tumors are heterogeneous diseases, carrying either an aggressive outcome with progression and/or metastasis, or an indolent clinical course with low mortality rates. Such heterogeneity is underlined by different genetic/epigenetic events resulting in the initial development and further progression of these tumors. Over the last decades, advances in molecular technologies provided an insight into the pathogenesis of GU tumors, and pointed out possible biomarkers to be used in order to stratify men whose risk to develop tumors with poor outcome and/or not responding to conventional therapeutic options is higher as compared to the general population. Furthermore, some of those biomarkers with prognostic/predictive potential may also play a role as potential therapeutic targets, in light of the recent development of targeted treatments, novel approaches and technologies, and improvements in conventional therapeutic options. This Special Issue is dedicated to investigating and describing the molecular mechanisms of GU tumorigenesis, and to reporting on novel molecules which can be used as potential therapeutic targets, as well as to broadening the use of established biomarkers. Both reviews and research articles focusing on these topics, expecially those applying findings from basic biology and clinical trials to tools fulfiling unmet clinical needs are welcome.
Prof. Dr. Luigi Cormio
Dr. Francesca Sanguedolce
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- bladder cancer
- biomarkers
- molecular mechanisms
- therapeutic targets
- translational research
